Punita Gupta
Chicago, ILNPI 1073709457
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,276 of the $177,082 with a category attached, or 67.9%. Sanofi accounts for 86.4% of it on its own, with 9 other manufacturers making up the rest.
Across 147 payments — averaging $1204.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$153K
- Shire North American Group Inc$19K
- Amicus Therapeutics, Inc.$5K
- Biomarin Pharmaceutical Inc.$126
- Sanofi-aventis U.S. LLC$56
- Takeda Pharmaceuticals U.S.A., Inc.$37
- plus $71 from 4 others
Across 19 payments — averaging $1805.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- Biomarin Pharmaceutical Inc.$12K
- Sanofi US Services Inc.$7K
- Shire North American Group Inc$572
What the payments were for
- Consulting fees$28,87816%
- Speaking & faculty fees$120,27668%
- Travel & lodging$25,39914%
- Food & beverage$2,5271%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 121 | $152,985 |
| Shire North American Group Inc | 8 | $18,840 |
| Amicus Therapeutics, Inc. | 8 | $4,967 |
| Biomarin Pharmaceutical Inc. | 3 | $126 |
| Sanofi-aventis U.S. LLC | 1 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Soleno Therapeutics, Inc. | 1 | $29 |
| Springworks Therapeutics, Inc. | 1 | $24 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$95,298
- LUMIZYME$29,309
- CERDELGA$17,000
- CEREZYME$17,000
- ALDURAZYME$12,946
- NEXVIAZYME$8,520
- VPRIV$5,680
- DISEASE STATE$1,764
- NO PRODUCT DISCUSSED$835
- POMBILITI$590
- OPFOLDA$590
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.